Ivosidenib is an inhibitor that helps treat relapsed or tough-to-treat acute myeloid leukemia with IDH1 mutations. It is formulated as 250 mg film-coated tablets, and the recommended dose is 500 mg taken once daily by mouth. You can get it in bottles with 60 tablets.
It works by going after that faulty IDH1 enzyme to slow down cancer cell growth. It’s mainly for people who didn’t get better or had a return of their disease after trying other treatments first.
